George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's not guaranteed that there will be a fundraise because money could come into the company via collaboration(s).
We've got to remember that a Director bought £100K worth recently at 29.6p so he must think that was a good SP to buy at and if there was a fundraise it can't be lower than that SP as might as well wait until their director buy.
I was over exposed in this share as bought more for the phase III rise results therefore took some profit but won't be selling another share in this company for a long time and excited for the future and to own a small share in this business.
Good luck to all genuine long term holders.
Haha I wish Spencer id say he’s made a million investing if you listen to his calculations in a recent video I’m not there yet :-P only made £12k here had to settle for half a bag instead of a full one but wanted to load up elsewhere I’ll be back in here before FDA and if I have to pay a premium to what I sold then that doesn’t bother me so you wot see me trying to talk this down!
yep,, there will be a fundraise for sure, however it won't be one with any meaningful discounts (or warrants) as the reality here is that it presents the perfect (and rare) opportunity for large de-risked institutional investment... the test of patience begins and i am more than happy to sit it out :)
Nice one Brooko19 (I mean Justin Waite) ;-)
I sold out @36 see it drifting till FDA... be a fundraiser before then IMO GLA
Director buy last week at 29.6p - he's an insider so good enough for me!
Nice on Jimzi, I'm going to take my chances and see if it drifts now to Q3.
Best of luck.
Got another 100k sb at 33.09.
No brainer now
Well done everyone, derisked now waiting for FDA approval. In the grand scheme of things Q3 isn’t far away at all.
Not forgetting the way is now open for collaboration agreements. They will be big sp kickers.
Defo be volatile for a bit while the enormity of what now will happen sinks in. FDA approval virtually a certainty. Should see a VRS style re- rate but here the story is proven.
The financials have just become reality
GL
Well done everyone! Hopefully get over 40p now. It will then probably drift back during FDA process.
GLA.
Will open 20% up see if it keeps going or gets sold into..
Positive phase III results. Numerous big director buys at this SP level and higher lately says it all. SP should motor today and traders buying back in!!!!
Yes it will be. I would usually expect the market to adjust quite quickly but this is under the radar. Sorry the link did not work...it’s different to IHub.
"The use of conventional, anatomical MRI has, historically, not played a role in addressing the substantial unmet need in working up difficult-to-diagnose pulmonary diseases. The innovative approach we have taken with the use of hyperpolarized 129Xenon gas opens up a whole new window into how physicians diagnose, stage and monitor responses to treatment in a broad range of lung diseases with this high resolution, non-ionizing MRI method. Based on what has been demonstrated in these Clinical Trials, we are excited about the prospect of having the Company's technology available as an additional tool to potentially make a clinically significant impact in the future."
http://www.polarean-ir.com/content/news/archive/2020/290120.asp
For the link
Be interesting to see market reaction today... take off or drift to Q3 when FDA submission.. GLA
Good news and great results. Good luck all
Polarean Imaging plc (AIM: POLX), a clinical stage medical imaging technology company developing a proprietary magnetic resonance imaging (MRI) drug-device combination, announces positive top-line results from two pivotal Phase III clinical trials (the "Clinical Trials") of the Company's drug-device combination, which uses hyperpolarized 129Xenon gas MRI to visualise and quantify regional lung function.
The drug, 129Xenon, when polarised in Polarean's proprietary system, permits functional, regional and quantitative imaging of the lungs using MRI, without the use of ionizing radiation. 129Xenon is administered as an inhaled gas that is given to patients in a 10-second breath-hold procedure. For patients who participated in the Clinical Trials, the ventilation in zones of interest was quantified and compared to images, similarly quantified, but derived from a different imaging modality.
Phase III Clinical Trials Data Demonstrate Effective Measurement of Regional Lung Ventilation
The two Clinical Trials were multi-center, randomised, open-label studies that compared MRI with 129Xenon gas, polarised in Polarean's system, to 133Xenon scintigraphy. These tests were used to measure regional pulmonary function in patients being evaluated for possible lung resection surgery and possible lung transplant surgery.
Both Clinical Trials met their primary endpoints, within the prospectively defined equivalence margin (+/-14.7%) when compared to the FDA-approved reference standard, 133Xenon scintigraphy imaging.
Lung Resection Trial
The surgical resection trial of 32 patients, required investigators to specify lung zones that would likely be resected if the patient received resection surgery. This trial compared each imaging modality's prediction of the proportion of lung function that would remain if the zone(s) were removed, this was expressed as a percentage remaining function. The intra-patient mean difference between 129Xenon MRI-predicted remaining function and 133Xenon scintigraphy-predicted remaining function was 1.4% with a 95% confidence interval of (-0.75%, 3.60%).
Lung Transplant Trial
In the lung transplant trial of 48 patients, the intra-patient mean difference between the imaging modalities measurement of the contribution of right lung to total lung function (percentage function) was -1.59% with a 95% confidence interval of (-3.69%, 0.50%).
Hyperpolarized 129Xenon gas inhalation and the 10 second breath procedure were well tolerated. Data from these Clinical Trials are being submitted for presentation at an upcoming scientific conference.
In addition, data from the Clinical Trials will form the basis of a Pre-New Drug Application ("NDA") Meeting with the U.S. Food and Drug Administration ("FDA"). Following the Pre-NDA Meeting and incorporation of the conclusions of the Clinical Trials into the NDA submission, Polarean plans to submit an NDA for the drug-device combination to the FDA, which is now estimated for Q3